Guo‐Ming Shi

机构：Fudan University, Zhongshan Hospital · ORCID：0000-0003-3817-9117

发表论文 180 篇 · 总被引 6864 次 · h-index 42

代表论文

• Oncolytic virus VG161 in refractory hepatocellular carcinoma (2025 · Nature · 被引 82)
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma (2024 · Nature Communications · 被引 47)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version) (2023 · Journal of Clinical and Translational Hepatology · 被引 21)
• Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma (2023 · International Immunopharmacology · 被引 16)
• First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study (2025 · Signal Transduction and Targeted Therapy · 被引 8)